Victoria Johnson

Other recent research presented at ACR 2024 found increased CVD risk with glucocorticosteroid use.

Zaheer discussed how this research may be used as a model to help study other therapy transitions as well.

Less than half of rheumatologists self-reported adhering to febuxostat and allopurinol dosing recommendations.

Schultz discussed the SCtalk trial and its findings at ASH 2024.

Pipe discussed a symposium at ASH 2024 about practical implementation of gene therapy in the field.

An active comparator study found that incident use of gabapentin was associated with lower rates of falls than duloxetine and similar rates of severe falls.

Listen Key Takeaways Deucravacitinib achieved ACR20 response in psoriatic arthritis phase 3 trials, potentially becoming the first TYK2 inhibitor for this condition.

Despite improvements in PROs and disease activity, no statistically significant changes have been seen on blood biomarker analysis.

Listen Key Takeaways CT-P42 demonstrated therapeutic equivalence to reference aflibercept in improving BCVA and retinal thickness in DME patients.

The biosimilars month in review highlights a newly approved ustekinumab biosimilar and a look into the field in 2024.